BENDAMUSTINE HCL

BENDAMUSTINE HCL
Product Description

For sure Bendamustine HCl is of interest to your company. Our API has been successfully registered in several European countries and is currently being registered in the US. REGULATORY STATUS: GMP: NO but WC - US-DMF: YES - EU-DMF: YES - COA: EP USP  - TSE/BSE: YES. www.dcspharma.com/bendamustine

Read more Show less

DCS Pharma USA

  • CH
  • 2018
    On CPHI since
View company profile
Categories
more categories Show less
Specifications
  • CAS Registry Number
    3543-75-7
More specifications Fewer specifications

DCS Pharma USA

  • CH
  • 2018
    On CPHI since
View company profile

More Products from DCS Pharma USA (2)

  • BORTEZOMIB

    Product BORTEZOMIB

    With earlier than expected entry of the generic into the US, the market potential of Bortezomib is expected to increase significantly. Be the first in the market with our technical and regulatory support. REGULATORY STATUS: US-DMF: YES - US-FDA inspection: Q4-2018 - EU-DMF: Submitted Q4-2017
  • DAPAGLIFLOZIN

    Product DAPAGLIFLOZIN

    Dapagliflozin inhibits the protein responsible for delivering glucose into the bloodstream. REGULATORY STATUS: US-DMF: YES - US-FDA approval: Expected - EU-DMF: In preparation. www.dcspharma.com/dapagliflozin

DCS Pharma USA resources (1)

  • PORTFOLIO DCS PHARMA USA

    Brochure PORTFOLIO DCS PHARMA USA

    YOUR API EXPERTS: The highest quality, specialized knowledge, and transparency: this is what we bring to active pharmaceutical ingredients.We are your specialists with clearly-defined schedules, extensive high-quality Swiss services, and a global network built up over decades. We focus on a few select therapeutic groups and set the right priorities.Because we’re quality-conscious.